Expanding the existing research findings in ADFH individuals with ApoE-4 carriers, although such a group has been demonstrated to show subclinical cognitive problems [24,25,26], the ApoE-4 group relative to the non-ApoE-4 group at this stage only partly exhibited worse neuropsychological (e.g., lower ARs) and neurophysiological (greater decreases in oscillatory power at the alpha band) in the higher working-memory-load (i.e., 4-item condition), but not the AD and neurocognition-related molecular biomarkers in the present study. The gene discussed is APOE; the disease is Alzheimer disease.